Atea Pharmaceuticals announces availability of press release on AT-587 Phase 1 trial start - AVIR News | RalliesAtea Pharmaceuticals announces availability of press release on AT-587 Phase 1 trial start
A
AVIR• AT-587 Phase 1 trial begins
- Atea Pharmaceuticals launched a first-in-human Phase 1 trial of AT-587 for hepatitis E virus.
- Randomized, double-blind, placebo-controlled study tests safety, tolerability, pharmacokinetics in healthy volunteers.
- Trial includes single-ascending dose, multiple-ascending dose, food-effect assessment.
- AT-587 is positioned as a potential first-in-class oral antiviral for HEV, a disease with no approved therapies.
REAX
•
